| Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2017-05-02 | ImCheck Therapeutics (France) | €20 million | series A financing round | Boehringer Ingelheim Venture Fund (BIVF) (Germany) Kurma Partners (France) Idinvest (France) Gimv (Belfium) LSP (The Netherlands) | Cancer - Oncology - Immunological diseases | Series A financing round |
| 2017-05-02 | Exocobio (Republic of Korea) | $11 million | series A financing round | SBI Investment (Republic of Korea) Atinum Investment (Republic of Korea) ID Ventures (Republic of Korea) Dt&Investment (USA - PA) | Autoimmune diseases - Dermatological diseases | Series A financing round |
| 2017-04-28 | Agios Pharmaceuticals (USA - MA) | $287 million | private placement | Cancer - Oncology - Genetic diseases - Metabolic diseases | Private placement | |
| 2017-04-26 | RegenXBio (USA - MD) | $87.2 million | private placement | Rare diseases - Genetic diseases | Private placement | |
| 2017-04-24 | Oryzon Genomics (Spain) | $300,000 | grant | Alzheimer’s Drug Discovery Foundation (ADDF) (USA - NY) | Neurodegenerative diseases | Grant |
| 2017-04-21 | Galapagos (Belgium) | €363.9 million | capital increase | Capital increase | ||
| 2017-04-19 | Synpromics (UK) | £5.2 million | financing round | Calculus Capital (UK) Scottish Investment Bank (UK) private shareholders | Technology - Services | Financing round |
| 2017-04-17 | Arena Pharmaceuticals (USA - CA) | $79.4 million | private placement | Private placement | ||
| 2017-04-13 | Delmar Pharmaceuticals (USA - CA) | $ 9 million | private placement | Cancer - Oncology | Restructuring | |
| 2017-04-12 | Polyphor (Switzerland) | CHF 40 million (€ 37.43 million) | private placement | Varuma (Switzerland) Ingro Finanz (Switzerland) | Infectious diseases | Private placement |
| 2017-04-10 | Adaptimmune (UK) | $42 million | private placement | Matrix Capital (USA - MA) | Cancer - Oncology | Private placement |
| 2017-04-04 | Novosanis (Belgium) | € 200 000 | grant | Interreg CrossCare (Belgium) | Infectious diseases - Diagnostic | Grant |
| 2017-04-04 | Repositive (UK) | £2.5 million (€ 2.92 million) | series A financing round | Ananda Social Venture Fund (Germany) Force Over Mass Capital (UK) Amadeus Capital Partners (UK) Jonathan Milner | Technology - Services | Fundraising |
| 2017-04-03 | Mereo BioPharma (UK) | £15.0 million | private placement | Rare diseases - Genetic diseases | Private placement | |
| 2017-03-31 | Osmia Pharmaceuticals (Sweden) | SEK 42 million (€ 4.4 million) | private placement | Cancer - Oncology - Veterinary medicine | Private placement | |
| 2017-03-31 | Aveo Pharmaceuticals (USA - MA) | $15.0 Million | private placement | Private placement | ||
| 2017-03-30 | Cidara Therapeutics (USA - CA) | $6.9 million | grant | CARB-X (Combating Antibiotic Resistant Bacteria Accelerator) (USA) | Infectious diseases | Grant |
| 2017-03-30 | Tango Therapeutics (USA - MA) | $55 million | series A financing round | Third Rock Ventures (USA - MA) | Cancer - Oncology | Fundraising |
| 2017-03-30 | Forge Therapeutics (USA - CA) | $8.8 million | grant | CARB-X (Combating Antibiotic Resistant Bacteria Accelerator) (USA) | Grant | |
| 2017-03-28 | Nosopharm (France) | €2.4 million | financing round | Auriga Partners (France) Kreaxi (France) Alto Invest (France) | Infectious diseases | Capital increase |
